ClinicalTrials.gg
RecruitingNCT06424665Updated Mar 4, 2026

A Study of FZ-AD005 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of FZ-AD005 in Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
162
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Planned enrollment
101st of 333
162 · median 63
Started
2024
with 51 others
Phase 1
43 of 365
24 open now
Primary completion
2026-08
later than 62 of 214 live
Registered
216th of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 101st largest by planned enrollment of the 333 interventional ones that give a count, is one of 52 that started in 2024, is one of 43 in phase 1, reaches primary completion later than 62 of the 214 other live ones, and was the 216th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 366 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 266 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.

03

Conditions studied

  • Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients able to give written ;
  2. Age ≥ 18 and ≤ 75 years old, male or female;
  3. Patients have histological or cytological diagnosis with advanced solid tumors ( especially SCLC or LCNEC);
  4. Willingness to provide tumor tissue for testing ;
  5. Have defined in v. 1.1;
  6. Expected survival ≥ 3 months;
  7. Eastern Cancer Cooperative Group () performance status 0-1;
  8. Patients of child bearing potential must agree to take during the study and for 6 months after the last day of treatment.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have had previous treatment with any anti-DLL3 antibody;
  2. Have had other malignant tumors in the past 5 years;
  3. Patients who are receiving other anti-tumor treatments within 4 weeks prior to the first dose;
  4. Have active CNS (central nervous system) ;
  5. Had undergone major surgery or severe trauma within 4 weeks prior to the first dose;
  6. Had undergone systemic high-dose within 2 weeks of initiation of study treatment;
  7. Patients have psychiatric history;
  8. Female patients who are breastfeeding or pregnant;
  9. Other reasons that researchers believe are inappropriate to participate in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    FZ-AD005

    Drug: FZ-AD005

Interventions

  • DrugFZ-AD005

    Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.

06

What researchers measure

Primary outcomes

  1. The dose limiting toxicity ( DLT)

    To determine the dose limiting toxicities (DLTs) of FZ-AD005

    Time frame: 21 Days (first cycle)

  2. Maximum Tolerable Dose (MTD)

    To determine the maximum tolerated dose (MTD) and/or recommended doses for expansion (RDEs). RDEs will not exceed MTD.

    Time frame: 21 Days (first cycle)

  3. Adverse Events (AEs)

    To check the numbers of AEs happened during the course of trial.

    Time frame: Screening up to study completion, assessed up to 60 months

  4. Objective Response Rate (ORR)

    To evaluate the objective response rate (ORR) \[Complete Response (CR) + Partial Response (PR)\] of FZ-AD005 according to RECIST 1.1

    Time frame: Up to 60 months

Secondary outcomes

  1. Progression free survival(PFS)

    Progression-free survival (PFS) was defined as the interval from the first dose start date to the date of disease progression defined as documented progressive disease (PD) or death from any cause, whichever occurs first.

    Time frame: Up to 60 months

  2. Duration of Response(DOR)

    Duration of Response was defined as the duration of overall response measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).

    Time frame: Up to 60 months

  3. Overall Survival (OS)

    overall survival was defined as the time from the date of the first dose start date to the date of death due to any cause.

    Time frame: Up to 60 months

  4. Anti Drug Antibody (ADA)

    To check the" Anti Drug Antibody" develops in participants against the FZ-AD005 through blood sample

    Time frame: Up to 36 months

  5. Time to peak (Tmax)

    To measure the time to reach the maximum contraction of Total Antibody, Free DXd and FZ-AD005 in study participants

    Time frame: Up to 18 weeks

  6. Terminal elimination half-life (t1/2)

    To measure the time of Total Antibody, Free DXd and FZ-AD005 will take to eliminate half of it's concentration from participants.

    Time frame: Up to 18 weeks

  7. Maximum observed plasma concentration (Cmax)

    To measure the maximum concentration participants obtained of Total Antibody, Free DXd and FZ-AD004 in their blood plasma.

    Time frame: Up to 18 weeks

  8. Area under the concentration-time curve (AUC 0-∞) from time 0 to infinity

    To measure the drug profile for absorption, distribution, metabolism and excretion for Total Antibody, Free DXd and FZ-AD005 in participants blood plasma

    Time frame: Up to 18 weeks

  9. Time to Cmax (Tmax)

    To measure the time to reach the maximum contraction of Total Antibody, Free DXd and FZ-AD005 in study participants

    Time frame: Up to 18 weeks

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Aug 2026, 24 months after the start.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's planned 24 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2024
First posted
May 22, 2024
StartActual
Jul 3, 2024
Primary completionEst.
Aug 1, 2026
CompletionEst.
Dec 1, 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06424665
Responsible party
Sponsor
First posted
May 22, 2024
Start date
Jul 3, 2024
Primary completion
Aug 1, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Mar 4, 2026

Study contacts

Mengli Zhou
Contact
mlzhou@fd-zj.com
00-86-021-58953355

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion